Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 · New England Journal of Medicine · 4,543 citations
https://doi.org/10.1056/nejmoa040766
M
Massimo Cristofanilli
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.4K
Papers
57.5K
Citations
111
h-index
426
i10-index
Massimo Cristofanilli is an academic researcher from Northwestern University. The author has contributed to research in topics: Cancer Cells and Metastasis & Cancer Genomics and Diagnostics & Advanced Breast Cancer Therapies. The author has an h-index of 111, co-authored 1224 publications.
ORCID: 0000-0002-4194-7175Papers by this author
worksResponse to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
2008 · Journal of Clinical Oncology · 2,876 citations
https://doi.org/10.1200/jco.2007.14.4147
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
2005 · Clinical Cancer Research · 1,869 citations
https://doi.org/10.1158/1078-0432.ccr-04-2421
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 · The Lancet Oncology · 1,795 citations
https://doi.org/10.1016/s1470-2045(15)00613-0
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
2015 · New England Journal of Medicine · 1,569 citations
https://doi.org/10.1056/nejmoa1505270
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
2018 · New England Journal of Medicine · 1,220 citations
https://doi.org/10.1056/nejmoa1810527
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat